Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Trial Profile

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mesothelioma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions
  • Acronyms TRuST
  • Sponsors Epizyme
  • Most Recent Events

    • 23 Apr 2018 According to an Epizyme media release, patients enrollment has been suspended in USA location, due to a safety report of a pediatric patient who developed a secondary lymphoma. Patients on study who have not experienced disease progression may continue to receive tazemetostat. The company has begun the modifications to resume this partial clinical hold in USA.
    • 14 Jun 2017 According to an Epizyme media release, interim efficacy data from the study has been presented during a plenary session at the International Conference on Malignant Lymphoma (ICML) 2017.
    • 14 Jun 2017 Results published in an Epizyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top